Abstract 1351: Preclinical characterization of BMS-986288, a novel non-fucosylated (NF) anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) Probody<i>®</i> therapeutic
Amy Jhatakia(Sequoia Hospital), Nicholas Wilson(Sequoia Hospital), Alan J. Korman(Bristol-Myers Squibb (Germany)), Joshua Dobroff(Sequoia Hospital), Yun Wei(Sequoia Hospital), John Engelhardt(Bristol-Myers Squibb (United States)), Courtni Newsome(The Bristol-Myers Squibb Children's Hospital), Mohammed Nasser(Sequoia Hospital), Felix Findeisen(Sequoia Hospital), Remie Gail Z. Mandawe(Sequoia Hospital), Neha Gupta(Sequoia Hospital), L L Leung(Gilead Sciences (United States)), Anandaroop Mukhopadhyay(University of Utah), Jack Lohre(Sequoia Hospital), Kyeongah Kang(Sookmyung Women's University), Karen Price(Purchase College), Mark Selby(Bristol-Myers Squibb (Germany))
Cited by 2
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714